In this issue:
- Palliative care for patients with end-stage liver disease
- Annual dynamic abbreviated MRI vs biannual ultrasound for HCC surveillance
- PFAS exposure increases the risk of HCC among individuals with cirrhosis
- Real-world outcomes of resection vs ablation in early-stage HCC
- Cirrhosis, portal hypertension and HCC
- Efficacy and safety results from the EMERALD-3 trial
- Adjuvant pembrolizumab after surgical resection or local ablation in HCC
- Pemigatinib for unresectable or metastatic cholangiocarcinoma
- Daraxonrasib vs chemotherapy for previously treated metastatic pancreatic cancer
- Histotripsy in patients with liver tumours
Please login below to download this issue (PDF)